GO
Loading...

Life Sciences

More

  • TOKYO, Oct 30- Japan's Fujifilm Holdings Corp said it was difficult to estimate the profitability of its influenza drug Avigan, which has been earmarked to fight Ebola, given the uncertainty over the spread of virus, a company executive said on Thursday. France and Guinea plan to conduct clinical trials of Avigan 200 mg tablets, made by Fujifilm group company...

  • UPDATE 1-Pfizer meningitis vaccine wins U.S. approval Wednesday, 29 Oct 2014 | 3:06 PM ET

    Oct 29- Pfizer Inc has won U.S. approval for its Trumenba vaccine against meningitis, a potentially deadly bacterial disease that has recently caused outbreaks on college campuses, the U.S. Food and Drug Administration said on Wednesday. It is the first approved U.S. vaccine that prevents invasive disease caused by the bacterium Neisseria meningitidis B, a...

  • LONDON, Oct 27- Drugmakers sprinting to develop Ebola vaccines face a series of technical hurdles if they are to get millions of doses ready for use next year-- even assuming clinical trials are successful. The challenges include finding sufficient sterile capacity for filling and packaging finished vials, getting fast quality approvals from regulators, and...

  • *Topic expected to be discussed at Geneva vaccines meeting. LONDON/ GENEVA, Oct 23- Drugmakers are looking for some kind of indemnity from governments or multilateral agencies against possible losses or claims arising from the widespread emergency use of new Ebola vaccines in Africa. While the issue will not delay the industry's ongoing work to accelerate...

  • *Topic expected to be discussed at Geneva vaccines meeting. LONDON/ GENEVA, Oct 23- Drugmakers are looking for some kind of indemnity from governments or multilateral agencies for the widespread emergency use of new Ebola vaccines in Africa. While the issue will not delay the industry's ongoing work to accelerate production and clinical testing of three...

  • *European Commission to provide 100 million euros. The move shows how momentum is building to get medical interventions-- and particularly vaccines-- to West Africa as soon as possible to control the world's worst Ebola outbreak, which, according to official figures, has killed nearly 5,000 people, most of them in Liberia, Sierra Leone and Guinea.

  • GSK sees first Ebola vaccine doses ready late this year Wednesday, 22 Oct 2014 | 8:08 AM ET

    LONDON, Oct 22- GlaxoSmithKline expects to have the first doses of its Ebola vaccine ready late this year and is looking to work with the rest of the pharmaceutical industry to scale up production. "I fully anticipate that the initial supply should be available before the year end," Chief Executive Andrew Witty told reporters on Wednesday after reporting...

  • *J&J says has discussed collaboration with GlaxoSmithKline. Johnson& Johnson said on Wednesday that it aims to produce at least 1 million doses of its two-step vaccine next year and has already discussed collaboration with Britain's GlaxoSmithKline, which is working on a rival vaccine. The World Health Organization hopes that tens of thousands of people in...

  • J&J, GSK ready to collaborate on Ebola vaccine work Wednesday, 22 Oct 2014 | 6:11 AM ET

    LONDON, Oct 22- Drugmakers will work together to accelerate development of an Ebola vaccine and Johnson& Johnson and GlaxSmithKline, both of which have experimental vaccine candidates, have already discussed collaboration. J&J, which aims to have at least 1 million doses of its two-step vaccine available next year, said on Wednesday that vaccine makers would...

  • LONDON, Oct 22- Johnson& Johnson is accelerating work on its experimental Ebola vaccine and said on Wednesday that it aims to have 1 million doses ready in 2015, of which 250,000 are expected to be available by May. There is currently no proven vaccine against the deadly disease but several companies are racing to develop products and clinical tests on two- from...

  • Oct 22- Johnson& Johnson said it has made a commitment of up to $200 million to accelerate and significantly expand the production of an Ebola vaccine program.

  • SYDNEY, Oct 17- Australian biotech firm CSL Ltd, the world's second-biggest blood products maker, said on Friday it's working on a plasma product to treat Ebola following a request from the Bill& Melinda Gates Foundation, part of a growing commercial response to the deadly outbreak. Along with CSL, Sydney- listed protective products maker Ansell Ltd, the world's...

  • SYDNEY, Oct 17- Australian biotech firm CSL Ltd, the world's second-biggest blood products maker, said on Friday it's working on a plasma product to treat Ebola following a request from the Bill& Melinda Gates Foundation, part of a growing commercial response to the deadly outbreak. Along with CSL, Sydney- listed protective products maker Ansell Ltd, the world's...

  • NEA, known for backing companies such as Workday Inc, Salesforce.com Inc and Gilt Groupe, is one of the world's top venture firms, with its latest fund totalling $2.6 billion. Health science is one area where women venture capitalists appear to be making serious gains, with some of the most accomplished health investors, including Beth Seidenberg of Kleiner...

  • Oct 6- After nearly a week in hospital, the first Ebola patient diagnosed in the United States began to receive an experimental therapy initially developed to treat other viral diseases, according to the Dallas hospital where he lies in critical condition. On Monday, however, a spokeswoman for Texas Health Presbyterian Hospital said Duncan began receiving a...

  • While Lilly's shares hardly budged on the news, the ADRs of Israel- based XTL Biopharmaceuticals Inc, which is developing its own lupus treatment, nearly tripled to $5.00. About 1.5 million people in the United States are estimated to suffer from lupus, according to the U.S. Centers of Disease Control and Prevention. The U.S. Food and Drug Administration approved...

  • Oct 1- An experimental cholesterol-fighting drug being developed by Esperion Therapeutics Inc lowered LDL levels significantly more than Merck& Co Inc's Zetia in a midstage clinical trial, Esperion said on Wednesday. The LDL reductions seen with the once-daily ETC-1002 pill were somewhat less than can be achieved by more powerful statins, such as Pfizer...

  • Oct 1- A new type of experimental cholesterol fighter being developed by Esperion Therapeutics Inc lowered LDL levels significantly more than Merck& Co Inc's Zetia in a midstage clinical trial, the company said on Wednesday.

  • NEW YORK, Oct. 1- Two tiny companies are preparing to challenge some of the world's largest drug makers in the battle for dominance in the $3 billion global market for influenza vaccines, armed with little more than tiny tobacco plants.

  • Sept 30- Johnson& Johnson said it would buy privately held drug developer Alios BioPharma Inc for $1.75 billion in cash, to access a portfolio of drugs targeting viral infections. Johnson& Johnson said the deal includes Alios's experimental drug for infants with respiratory syncytial virus.